Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radio...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2022-04-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actadv/article/view/293 |
| _version_ | 1811329785373130752 |
|---|---|
| author | Martin Kaatz Peter Mohr Elisabeth Livingstone Michael Weichenthal Alexander Kreuter Claudia Pföhler Ulrike Leiter Jens Ulrich Jochen Sven Utikal Ralf Gutzmer Rudolf Herbst Dirk Schadendorf |
| author_facet | Martin Kaatz Peter Mohr Elisabeth Livingstone Michael Weichenthal Alexander Kreuter Claudia Pföhler Ulrike Leiter Jens Ulrich Jochen Sven Utikal Ralf Gutzmer Rudolf Herbst Dirk Schadendorf |
| author_sort | Martin Kaatz |
| collection | DOAJ |
| description | Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radiotherapy, or for patients with symptomatic metastatic BCC. In order to enhance understanding of the effectiveness, safety and utilization of vismodegib in clinical practice in Germany, a non-interventional study, JONAS, was conducted. A total of 53 patients with locally advanced BCC who initiated treatment with vismodegib between 2016 and 2018 were included in the study, which was embedded in the German ADOReg skin cancer registry. Duration of response, the primary endpoint, was 12.4 months, progression-free survival 32.2 months and overall response rate 77.4%. Most adverse events were mild to moderate. Overall, results confirmed previous findings, demonstrating favourable responses and manageable safety of vismodegib in patients with locally advanced BCC in clinical practice.
|
| first_indexed | 2024-04-13T15:50:06Z |
| format | Article |
| id | doaj.art-a3c3ac9b536a4c41ab20bf32d592e730 |
| institution | Directory Open Access Journal |
| issn | 0001-5555 1651-2057 |
| language | English |
| last_indexed | 2024-04-13T15:50:06Z |
| publishDate | 2022-04-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj.art-a3c3ac9b536a4c41ab20bf32d592e7302022-12-22T02:40:52ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572022-04-0110210.2340/actadv.v102.293Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONASMartin KaatzPeter MohrElisabeth LivingstoneMichael WeichenthalAlexander KreuterClaudia PföhlerUlrike LeiterJens UlrichJochen Sven UtikalRalf GutzmerRudolf HerbstDirk Schadendorf0Department of Dermatology, University Hospital Essen, Hufelandstr. 55, DE-45122 Essen, GermanyMost patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radiotherapy, or for patients with symptomatic metastatic BCC. In order to enhance understanding of the effectiveness, safety and utilization of vismodegib in clinical practice in Germany, a non-interventional study, JONAS, was conducted. A total of 53 patients with locally advanced BCC who initiated treatment with vismodegib between 2016 and 2018 were included in the study, which was embedded in the German ADOReg skin cancer registry. Duration of response, the primary endpoint, was 12.4 months, progression-free survival 32.2 months and overall response rate 77.4%. Most adverse events were mild to moderate. Overall, results confirmed previous findings, demonstrating favourable responses and manageable safety of vismodegib in patients with locally advanced BCC in clinical practice. https://medicaljournalssweden.se/actadv/article/view/293Locally advanced basal cell carcinomaVismodegibEffectivenessSafetyNon-interventional studyGerman ADOReg skin cancer registry |
| spellingShingle | Martin Kaatz Peter Mohr Elisabeth Livingstone Michael Weichenthal Alexander Kreuter Claudia Pföhler Ulrike Leiter Jens Ulrich Jochen Sven Utikal Ralf Gutzmer Rudolf Herbst Dirk Schadendorf Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS Acta Dermato-Venereologica Locally advanced basal cell carcinoma Vismodegib Effectiveness Safety Non-interventional study German ADOReg skin cancer registry |
| title | Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS |
| title_full | Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS |
| title_fullStr | Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS |
| title_full_unstemmed | Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS |
| title_short | Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS |
| title_sort | effectiveness safety and utilization of vismodegib for locally advanced basal cell carcinoma under real world conditions non interventional cohort study jonas |
| topic | Locally advanced basal cell carcinoma Vismodegib Effectiveness Safety Non-interventional study German ADOReg skin cancer registry |
| url | https://medicaljournalssweden.se/actadv/article/view/293 |
| work_keys_str_mv | AT martinkaatz effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT petermohr effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT elisabethlivingstone effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT michaelweichenthal effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT alexanderkreuter effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT claudiapfohler effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT ulrikeleiter effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT jensulrich effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT jochensvenutikal effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT ralfgutzmer effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT rudolfherbst effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas AT dirkschadendorf effectivenesssafetyandutilizationofvismodegibforlocallyadvancedbasalcellcarcinomaunderrealworldconditionsnoninterventionalcohortstudyjonas |